News | Implantable Cardiac Monitor (ICM) | April 06, 2022

Insertable Cardiac Monitors (ICM) and Remote Monitoring May Improve Outcomes for Post-Myocardial Infarction Patients, Study Demonstrates

Presentation at ACC.22 shows early treatment of high-risk NSTEMI patients guided by continuous arrhythmia monitoring with ICMs may reduce major adverse cardiac events (MACE)

Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of patients with non-ST segment elevation myocardial infarction (NSTEMI).

April 6, 2022 – Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of patients with non-ST segment elevation myocardial infarction (NSTEMI). In the primary endpoint analysis of the total patient population, a trend towards MACE reduction in the ICM group was observed but did not reach statistical significance. The outcomes were presented by coordinating investigator Dr. Christian Jøns, Rigshospitalet Copenhagen, at a Late-Breaking Clinical Trial session at the American College of Cardiology’s 71st Annual Scientific Session in Washington D.C. on April 4th.

The study was led by Dr. Christian Jøns, Prof. Peter Søgaard, and Prof. Poul Erik Bloch Thomsen, Aalborg University Hospital, and Prof. Steffen Behrens, Vivantes Humboldt-Klinikum, Berlin, and sponsored by BIOTRONIK. The randomized, controlled, prospective, multi-center, international study enrolled 802 patients in 60 sites across Europe, Australia and the US between August 2015 and April 2020. The primary composite study endpoint was time to first MACE. The study included post-myocardial infarction patients with high risk defined by CHA2DS2-VASc score ≥4 (men) or ≥5 (women).

"Myocardial infarction is a leading cause of death globally and patients are at increased risk of major adverse events post-MI," commented Dr. Christian Jøns, Rigshospitalet Copenhagen, Denmark. "We knew that arrhythmias are a strong predictor for adverse outcomes but they often remain unnoticed by conventional follow-ups. BIO|GUARD-MI is the first study which has investigated whether monitoring and responding to arrythmias with ICMs via Home Monitoring can improve clinical outcome in post-MI patients – and we used procedures in a real-world-setting that can be applied everywhere."

In addition to showing a reduction of MACE in NSTEMI patients, the continuous monitoring identified a large arrhythmia burden (at 2 years, 67.3% of the ICM group had a first arrhythmia detected) and showed that patients in the ICM group received guideline-recommended treatment, in response to arrhythmia detection, more often than the control group (39.4% vs. 6.7%).

"The lack of a benefit in STEMI patients surprised us all, but we found that they have a lower risk to suffer a subsequent major adverse cardiac event. And it appears to be the higher risk that makes arrhythmia monitoring effective in NSTEMI patients," said Prof. Peter Søgaard, Aalborg University hospital, Denmark. "Keeping a close eye on the patients remotely could turn out to be very useful because the patients with the highest risk have the highest benefit."

"After their hospital discharge, myocardial infarction patients are usually seen for follow-up by their GP or cardiologist at extended intervals, despite their high cardiovascular risk. We have developed the technology to identify when they need attention, not only when the calendar says so. We will explore with clinicians and the scientific community how we can use our ICM and Home Monitoring capabilities to improve care and outcomes of post-myocardial infarction patients and how this may be translated to clinical practice and guidelines," added Dr. Klaus Contzen, Vice President Clinical Affairs, Center for Clinical Research, BIOTRONIK.

For more information: www.biotronik.com

Find more ACC22 content here


Related Content

News | ACC

Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on ...

Home November 05, 2022
Home
News | ACC

July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer ...

Home July 15, 2022
Home
Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
Subscribe Now